宝石能谱CT多参数成像在鉴别前列腺癌与前列腺增生结节中的价值

目的 探讨能谱CT多参数成像在鉴别前列腺癌(PCa)与前列腺增生(BPH)结节中的价值.方法 前瞻性纳入本院超声首诊提示前列腺结节(性质待查)并行3.0 T MRI常规三平面T2 WI扫描患者91例,并严格排除20例不符合标准患者,最终纳入PCa(n =33)、BPH(n =38)71例,年龄50～84岁,平均(62.8±7.52)岁;71例患者均行前列腺能谱成像.(1)图像处理:参照MRI定位前列腺结节,2名观察者独立测量前列腺结节的单能量、混合能量图CT值、有效原子序数,取3次测量值的平均值;(2)数据处理:采用独立样本t检验分别比较PCa和BPH的单能量CT值、混合能量CT值与有效原子序数之间的差异;分别按斜率=(CT40 keV-CT100 keV)/60计算两组结节在40～90 keV条件下能谱曲线斜率,其差异采用非参数秩和检验(Mann-Whitney U)比较;绘制不同能量与有效原子序数ROC曲线,并计算相应AUC值和95％CI值;P＜0.05差异有统计学意义.结果 2名观察者主观评分显示70～90 keV单能量显示解剖较好;PCa和BPH所测CT值及斜率均符合正态分布;BPH与PCa在40 ～80 keV时差别较明显.PCa与BPH在40 ～ 70 keV的单能量CT值存在统计学差异[40 keV(t=5.507、P=0.000)、50 keV(t=5.453、P＜ 0.000)、60 keV(t =4.422、P=0.0003)、70 keV(=2.889,P=0.0094)];但在80 ～140 keV时显示两组无显著统计学差异;混合能量比较BPH与PCa无统计学差异(t=0.8883,P=0.3953);有效原子序数间比较BPH与PCa具有统计学差异(t=3.869,P=0.001);能谱曲线斜率Mann-Whitney U比较,40 keV (U=64、P=0.000)、50 keV(U=63、P=0.0002)、60 keV(U=65、P=0.0003)、70 keV(U=71.5、P=0.0005)、80 keV(U=83、P=0.0005)、90 keV(U=63、P=0.000)均有统计学差异.ROC曲线显示40 keV、50 keV、有效原子序数均有较高准确性,对应的AUC均＞0.9;80～ 100 keV有低准确性(AUC 0.5 ～0.7);110 ～ 140 keV无诊断价值(AUC ＜0.5).结论 能谱CT多参数成像在鉴别明确病灶部位PCa与BPH结节的良恶性时具有一定的参考价值.     

良性前列腺增生与前列腺癌的MSCT多期强化特征的比较

目的探讨良性前列腺增生(BPH)和前列腺癌(PCa)的多层CT(MSCT)多期扫描的强化特征。方法35例BPH和27例PCa病人术前行MSCT扫描,观察BPH和PCa的CT强化峰值到达的期相、最大强化幅值及时间-密度曲线,并计算曲线升段的斜率。结果两组病例强化峰值到达的期相及时间-密度曲线类型分布的差异有统计学意义(P<0.01)。BPH和PCa的斜率分别为0.45±0.25和0.76±0.34,PCa的斜率大于BPH的斜率(P<0.05)。而BPH和PCa的最大强化幅值分别为(44.057±10.261)HU和(46.778±11.140)HU,两组之间的差异无统计学意义(P>0.05)。结论MSCT多期扫描能够显示BPH、PCa的血供情况及强化特征,对前列腺病灶的显示和鉴别诊断起重要作用。     

CT能谱成像定量碘基物质图对肺栓塞的诊断价值

目的 评价CT能谱成像定量碘基物质图对肺栓塞(PE)的诊断价值.方法 53例怀疑PE的患者行CT常规平扫及能谱增强扫描,并进行数据后处理,同时获得单能量肺CTA及碘基物质图像.观察肺动脉内有无栓子,记录栓子的位置、数目及栓塞程度;分析碘基物质图表现,记录肺内灌注异常的位置及数目,测量碘含量.计数资料比较采用x2检验,不同碘含量比较分别采用两样本的秩和检验及符号秩和检验.结果 33例患者的碘基物质图密度均匀,CTA未显示PE;19例患者共显示93个栓子,其中肺叶26个,肺段54个,亚段13个.51个栓子为闭塞性,42个栓子为非闭塞性.所有闭塞性栓塞均有灌注减低表现,非闭塞性栓塞中11个显示灌注降低.CTA栓子的栓塞程度与肺内有无灌注减低区差异有统计学意义(x2=39.94,P＜0.01).正常肺实质区[(1.92±0.54)g/L]与灌注减低区[(0.30±0.20)g/L]碘基物质含量差异有统计学意义(Z=-5.63,P＜0.01).PE低灌注区抗凝治疗前[(0.26±0.23)g/L]与治疗后[(0.94±0.50)g/L]的碘基物质含量差异有统计学意义(Z=-3.93,P＜0.01).结论 CT能谱成像可以为PE提供定性、定量分析,可以作为评价病变程度以及指导治疗的有效手段.     

CT能谱成像对肝脏局灶性病变鉴别诊断价值的初步研究

目的 初步探讨能谱CT对常见肝脏局灶性病变的诊断和鉴别的临床应用价值.方法 51例肝脏局灶性病变患者,其中肝癌18例,单发微小转移瘤4例,异型增生结节(大再生结节)3例,单发肝脏小囊肿7例,血管瘤12例(18处病灶),肝脓肿5例,血管平滑肌脂肪瘤2例.均采用宝石能谱成像(GSI)模式扫描,获得平扫、动脉期、门静脉期的70 keY单能量图像和碘基、水基图像,利用GSI分析功能,观察不同肝脏占位性病变各期的能谱衰减曲线特点及基物质含量,比较不同局灶性病变间各期的碘基值、水基值及能谱曲线斜率[能谱曲线斜率=(HU40keV-HU90keV)/50]的差异,分别行独立样本t检验.结果 肝脏小囊肿斜率(1.20±0.50)与血管平滑肌脂肪瘤斜率(-1.40±0.62)因具有特异的组织构成,平扫即表现出特征性能谱曲线;肝血管瘤边缘部分碘含量在动脉期[(37.3±11.8) mg/mL]、门静脉期[(39.2±16.4) mg/mL]均高于小肝癌(15.8±7.3和23.6±4.5)、肝脓肿[(13.2±4.9) mg/mL和(21.9±10.2) mg/mL]和肝微小转移瘤[(9.5±7.2) mg/mL和(25.0±8.3) mg/mL];肝癌动脉期碘含量[(15.8±7.3 mg/mL]、能谱曲线斜率(2.14±0.92)高于异型增生结节(10.8±3.2和1.15±0.53),上述参数差异均具有统计学意义(P＜0.05).结论 通过CT能谱成像的能谱曲线、碘基含量可以反映肝脏局灶性病变的特有组织成分和血供特点,有助于肝脏局灶性病变的鉴别诊断.     

能谱CT成像鉴别肺结节性质的初步研究

目的:评价动脉期与静脉期能谱CT鉴别肺结节(≤3cm)性质的应用价值。方法:回顾性分析接受能谱CT双期扫描且经病理证实的肺结节48例,其中恶性结节与良性结节均为24例。分别测量动脉期(AP)和静脉期(VP)碘基物质密度图像上病灶和同层面主动脉的碘含量(IC),并计算两期病灶相对于主动脉的标准化的碘浓度值(NIC)及两期标准化碘含量之差ICD(ICD=NICVP-NICAP)。采用独立样本t检验的方法,比较良、恶性肺结节之间两期NIC及ICD的差异性,评估这些参数定量分析病灶的能力以及鉴别疾病的敏感度和特异度。结果:两期扫描中,恶性结节的两期NIC及ICD均显著高于良性结节:(NICAP0.198±0.038 vs.0.126±0.027,t=7.613,P<0.001;NICVP 0.473±0.118 vs.0.309±0.058,t=6.138,P<0.001;0.275±0.120 vs.0.183±0.051,t=3.469,P=0.002)。当NICAP阈值定为0.157、NICVP阈值定为0.420,ICD阈值定为0.256时,鉴别两组的敏感度及特异度分别为83.3%及87.5%、66.7%及100%、54.2%及100%。结论:能谱CT双期增强扫描可以对良、恶性肺结节的性质进行鉴别,且具有较高的敏感度和特异度及一定的临床应用价值。     

双源CT能谱成像在鉴别肾上腺无功能腺瘤与肾上腺转移瘤中的价值

目的探讨双源CT虚拟平扫技术及碘含量测定技术在鉴别肾上腺良恶性病变中的价值。方法搜集行肾上腺CT扫描者40例(共40个肾上腺结节),其中24个结节为无功能腺瘤,16个结节为转移瘤,对全部结节的动脉期及门静脉期常规平扫CT值、虚拟平扫CT值、碘含量(ICad)结果进行分析。结果动脉期肾上腺腺瘤平均ICad[(24.65±1.06)mg/ml]略高于肾上腺转移瘤[(22.85±9.53)mg/ml],差异有统计学意义(P=0.002),门静脉期肾上腺腺瘤ICad[(13.96±1.11)mg/ml]低于肾上腺转移瘤[(24.70±5.49)mg/ml],差异有统计学意义(P=0.036)。腺瘤与转移瘤的动脉期、门静脉期虚拟平扫平均CT值(Va、Vp)与常规平扫CT值(Vpre)差异无统计学意义;腺瘤的Vpre、Va、Vp均低于转移瘤,差异具有统计学意义(P=0.006、0.008、0.006)。结论双能量CT技术能够通过虚拟平扫技术及碘含量测定技术对二者进行鉴别诊断,以减少受检者经济负担及减轻辐射剂量。     

CT能谱成像在鉴别胰腺寡囊型浆液性囊腺瘤与黏液性囊性肿瘤中的价值

目的 探讨CT能谱成像定量分析在鉴别胰腺寡囊型浆液性囊腺瘤(SOA)与胰腺黏液性囊性肿瘤(MCNs)中的价值.方法 回顾性分析2010年2月至12月期间行能谱CT检查并经手术切除的胰腺囊性肿瘤27例,其中SOA为15例,MCNs为12例.采用x2检验比较两组间的非定量指标(性别、症状及病灶位置);采用t检验和Mann-Whitney检验比较定量指标(年龄、病灶大小、不同keV水平的CT值,有效原子序数,碘-水浓度,钙-水浓度),差异有统计学意义的指标通过判别分析法评估多参数联合诊断的价值.结果 与MCNs相比,SOA患者年龄较小、较少有症状、病灶较小.SOA的动脉期40～60keV及门静脉期40～50 keV CT值[分别为(36±13)、(26±8)和(19±6)HU,(43±14)和(30±10)HU],低于MCNs组上述期相和keV的CT值[分别为(62±23)、(40±15)和(27±10)HU,(61±25)和(40±16)HU](P＜0.05);SOA有效原子序数(动脉期和门静脉期分别为7.80±0.16和7.87±0.15)低于MCNs(动脉期和门静脉期分别为8.05±0.21和8.02±0.22)(P＜0.05);SOA动脉期的钙(水)浓度和碘(水)分别为(5±3)和(0.38±0.24)g/L,门静脉期分别为(7±3)和(0.48±0.24)g/L,均低于MCNs,动脉期分别为(11±4)和(0.78±0.32)g/L,门静脉期分别为(10±5)和(0.72±0.34)g/L(P＜0.05).判别分析结果显示,多参数联合[年龄、症状、病灶大小、40～50 keV的CT值、有效原子序数、动脉晚期碘(水)浓度及门静脉期钙(水)浓度]鉴别两者的准确率可达100%(27/27).结论 SOA与MCNs的囊性部分在CT能谱成像上具有不同特征.CT能谱成像多参数联合诊断可以准确区分SOA与MCNs.     

磁共振动态增强TIC曲线及Ktrans值在前列腺癌诊断中的对比

目的:对比研究磁共振动态增强TIC曲线及Ktrans值在前列腺癌诊断中的应用价值.方法:搜集本院行前列腺DCE-MRI以及穿刺病理活检的前列腺癌(PCa)及良性前列腺增生(BPH)各36例;DCE MRI原始数据经TISSUE 4D软件进行图像后处理,绘制病灶感兴趣区(ROI)及对侧对照ROI,绘制时间信号曲线(TIC)并进行PI RADS评分,测量定量参数Ktrans值,并进行统计学分析.结果:PCa组:病灶与对照ROI的PI-RADS评分均值分别为3.47、2.36,差异有显著统计学意义(P=0.000),病灶与对照ROI的Ktrans值分别为(0.270±0.151)/min、(0.216±0.116)/min,差异有统计学意义(P=0.028).BPH组:可疑病灶与对照ROI的PI-RADS评分均值分别为2.22、1.94,差异无统计学意义(P=0.069)、病灶与对照ROI的Ktrans值分别为(0.199±0.110)/min、(0.183±0.099)/min,差异无统计学意义(P=0.415).以PIRADS评分及Ktrans值诊断PCa的ROC曲线下面积分别为0.854、0.632.结论:DCE-MRI对前列腺癌的诊断提供了重要信息,其中TIC曲线的PI-RADS评分以及定量参数Ktrans值对诊断PCa有重要价值,前者诊断效能高于后者,诊断实践中宜综合应用.     

能谱CT碘浓度鉴别肾透明细胞癌病理Fuhrman分级

目的 评价应用能谱CT的能谱曲线及碘浓度值鉴别肾透明细胞癌(ccRCC)病理Fuhrman级别的可行性.方法 回顾性分析62例经病理证实的ccRCC 64个病灶的常规CT表现及增强皮髓质期(CMP)能谱CT表现,能谱CT主要参数包括能谱曲线斜率、标准化能谱曲线、碘浓度及标准化碘浓度(NIC),其中Fuhrman分级低级别(Ⅰ～Ⅱ级)35例,病灶37个,高级别(Ⅲ～Ⅳ级)27例,病灶27个,依据不同病理Fuhrman级别对肿物常规CT表现及能谱CT各参数进行统计学分析,并应用受试者工作特征曲线(ROC)和二项Logistic回归分析评价单独使用能谱CT或联合常规CT特征鉴别高级别和低级别ccRCC的能力. 结果 CMP高级别ccRCC的碘浓度值和NIC值显著低于低级别ccRCC(碘浓度36.57±9.62 mg/ml和49.65±11.42 mg/ml,P＜0.001;NIC 0.61 ±0.13和0.92±0.16,P＜0.001).碘浓度和NIC诊断高级别ccRCC ROC曲线下面积分别为0.811、0.935.最佳阈值、敏感度和特异度分别为:碘浓度0.811 mg/ml、81.1％、77.8％;NIC 0.745、86.5％、92.6％.采用二项Logistic回归分析,肿瘤大小(P=0.011)和肾周脂肪浸润(P =0.002)等常规CT影像学特征能作为鉴别高级别ccRCC的独立危险因素,将NIC列入Logistic回归模型可显著提高诊断高级别ccRCC的准确率(P =0.001).结论 高级别ccRCC的碘浓度值和NIC值显著低于低级别ccRCC,结合常规CT表现,可以提高鉴别高级别和低级别ccRCC的准确率,有助于治疗方案的选择和制定.     

CT能谱成像在胸腔渗出液与漏出液定性鉴别中的作用

目的 探讨CT能谱成像定量分析鉴别胸腔积液性质的价值.方法 将20例胸腔积液患者经胸腔穿刺术抽出的胸腔积液放在试管中进行能谱CT扫描,同时抽出的胸腔积液做胸水常规和生化检查.根据实验室检查结果,分为渗出液和漏出液.应用能谱分析软件,分析两组数据的常规混合能量140 kVp图像的CT值差异,以及两组数据的不同keV水平(40～140 keV)的CT值、能谱曲线斜率、有效原子序数、碘-水浓度、钙-水浓度、钙-脂肪浓度等CT能谱成像的定量参数间的差异.对渗出液和漏出液的CT能谱特征参数进行独立样本t检验.结果 根据实验室检查结果,20例中11例渗出液、9例漏出液.渗出液组的常规混合能量140 kVp的图像CT值[(19.56±4.10)HU]高于漏出液组[(13.44±3.46)HU],差异有统计学意义(t=3.002,P=0.010).keV能量越低,其CT值差别越大.在40keV,其CT值差异最大,分别是(47.49±14.60)、(19.76±6.85)HU,差异有统计学意义(t=5.520,P=0.000),渗出液明显高于漏出液;而在140 keV,其CT值差异无统计学意义,平均值分别是(9.76±4.16)和(6.22±3.17)HU(t=2.107,P=0.050).渗出液能谱曲线斜率(0.51±0.23)明显大于漏出液(0.18±0.08),差异有统计学意义(t=4.287,P=0.001).渗出液的有效原子序数、碘(水)浓度、钙(水)浓度、钙(脂肪)浓度明显高于漏出液组,两组的值分别为7.89±0.16和7.67±0.07、(5.74±1.28)和(1.70±0.95)g/L、(7.89±1.78)和(2.53±1.37)g/L、(25.95±1.74)和(20.82±1.40)g/L,差异均有统计学意义(t值分别为4.080、6.998、6.546、6.301,P值均＜0.05).结论 渗出液与漏出液具有不同的能谱曲线和能谱特征物质含量,低能量keV图像在渗出液的鉴别中起重要作用,能谱CT为鉴别胸腔积液的性质提供了一种多参数的方法.     

Repeat Prostatic Artery Embolization for Patients with Benign Prostatic Hyperplasia

PurposeTo evaluate the safety and efficacy of repeat prostatic artery (PA) embolization (PAE) for benign prostatic hyperplasia (BPH).Materials and MethodsA single-center retrospective study was conducted from 2009 to 2018 in 108 patients with symptomatic BPH treated with repeat PAE: group A (n = 39; 36.1%) were patients who never showed a response to PAE, and group B (n = 69; 63.9%) were patients who had clinical improvement in the first 6 months following PAE but relapsing symptoms afterward. The main patterns of revascularization were 75% from the previously embolized PA and 25% from collateral vessels (superior vesical, posterior-lateral PA, penile branches). Technical outcomes and adverse events were registered. International Prostate Symptom Score (IPSS), quality of life (QOL), and clinical success were compared between groups.ResultsMedian follow-up was 18 months (range, 1–36 mo); median interval between PAE and repeat PAE was 420 days (range, 77–2,240 d). Mean procedural time was significantly longer for repeat PAE vs initial PAE (81.1 min vs 67.4 min; P = .0007). There were no major complications and no urinary incontinence. Mean IPSS/QOL improvements were greater in group B vs group A: 9.51 vs 6.13 and 1.30 vs 0.56, respectively (P < .001). The cumulative probability of clinical success after repeat PAE was higher in group B than in group A (P = .0001): 84.1% vs 46.2% at 1 month, 56.7% vs 28.2% at 12 months, and 51.9% vs 16.9% at 24–36 months.ConclusionsRepeat PAE is safe and effective for recurrence of lower urinary tract symptoms caused by BPH but has limited impact in patients who did not show a response to initial PAE.     

Thickness-to-Height Ratio of Intravesical Prostatic Protrusion Predicts the Clinical Outcome and Morbidity of Prostatic Artery Embolization for Benign Prostatic Hyperplasia

PurposeTo evaluate the presence of intravesical prostatic protrusion (IPP) and its thickness-to-height (T/H) ratio as a predictor for the clinical outcome and morbidity of prostatic artery embolization (PAE) for benign prostatic hyperplasia.Materials and MethodsThis was a prospective, single-center, institutional review board-approved study from June 2015 to December 2018 of 82 consecutive patients (age, 53–79 years; median, 66 years) with International Prostate Symptom Score (IPSS) ≥15 and quality-of-life (QOL) score ≥3. The presence of IPP and its T/H ratio were assessed on baseline magnetic resonance imaging for their correlation with the clinical outcomes of suboptimal IPSS (IPSS ≥10) and suboptimal QOL (QOL ≥3) up to 12 months after PAE and the occurrence of post-procedure complications (≤30 days), which caused a certain degree of urinary outflow obstruction. The chi-squared test was used for analysis.ResultsIPP was present in 57 of 82 patients (69.5%). The presence of IPP correlated with the occurrence of post-procedure complications (P = .009) but not with suboptimal IPSS at 12 months (P = .758). IPP with a T/H ratio ≤1.3 correlated with suboptimal IPSS at 12 months (P = .025) and suboptimal QOL at 6 months (P = .025) and 12 months (P = .008), as well as with the occurrence of post-procedure complications (P = .009).ConclusionsIPP with a T/H ratio ≤1.3 predicted the occurrence of post-procedure complications with urinary obstruction. A T/H ratio ≤1.3 but not the presence of IPP alone predicted the clinical outcome up to 12 months after PAE.     

Intravesical Prostatic Protrusion Does Not Influence the Efficacy of Prostatic Artery Embolization

PurposeTo compare the outcomes of prostatic artery embolization (PAE) in patients with different intravesical prostatic protrusion (IPP) grades.Materials and MethodsThis retrospective single-center study included 128 patients (aged 50–86 years) who underwent PAE from 2013 to 2017. IPP grades were classified as follows: grade I (<10 mm), grade II (10–19 mm), and grade III (≥20 mm). Nineteen patients (14.8%) had grade I [mean IPP 7.8 mm, prostatic volume (PV) 64.1 cm³], 77 (60.2%) had grade II (mean IPP 14.9 mm, PV 87.0 cm³), and 32 (25%) had grade III (mean IPP 26.2 mm, PV 132.6 cm³), P < .01. The outcomes, including PV, international prostate symptom score (IPSS), and quality of life (QoL), were compared between the IPP grades at the 12-month follow-up. Clinical failure was defined as IPSS >7 or QoL >2.ResultsIPP decreased (I: ?8.2%, II: ?27.3%, and III: ?38.7%, P = .01), and all other endpoints improved (P < .01). Adjusted covariance analysis, considering baseline PV as a confounding factor, showed no correlation between the 12-month outcomes and baseline IPP. Clinical failure was observed in 17/128 patients (13.3%) and was similar in prevalence among the IPP groups (P = .20). Minor complications occurred in 43 patients (33.6%) and major in 3 (2.3%). There were statistical differences in the complications between IPP grades II and III (P < .01).ConclusionsPAE was similarly effective in all the IPP grades at the 12-month follow-up, and there was no difference in the clinical failure between the groups. Complications in IPP grade III were more frequent than those in IPP grade II.     

Repeat Prostatic Artery Embolization

This is a single-center retrospective analysis of 3 patients (mean age, 61 y ± 8.6) who underwent repeat prostatic artery (PA) embolization (PAE; rPAE) because of clinical failure after PAE. Revascularization of the central gland through a recanalized PA was the most frequent pattern observed (5 of 7; 71.4%), followed by revascularization through penile collateral vessels (2 of 7; 28.6%). Technical success during rPAE was achieved in 5 hemiprostates (83.3%). Clinical success at 6 months after rPAE was achieved in 2 of 3 patients (66.6%). Implications of these findings could be valuable to those performing PAE.     

MRI和PSA对前列腺癌和增生的诊断价值

目的　研究MRI和前列腺特异抗原 (PSA)对前列腺癌和增生的诊断能力。资料与方法　回顾性分析经手术病理证实的 2 6例前列腺癌和 4 0例前列腺增生的资料。研究MRI的表现并计算前列腺体积 ,结合以上病例血清PSA ,算出前列腺特异抗原密度 (PSAD)。结果　MRI对前列腺癌和前列腺增生的诊断准确率分别为 73.1%、80 %。按PSA肿瘤筛选界值PSA >10ng/ml作为标准 ,前列腺癌检出率为 6 9.2 % ,前列腺癌的误诊率为 2 2 .5 % ;按PSAD肿瘤筛选界值PSAD >0 .2 ,前列腺癌检出率为 92 .3% ,前列腺癌的误诊率为 5 %。结论　MRI和PSA结合可明显提高对前列腺癌和增生的诊断水平。     

Intra-vesical Prostatic Protrusion (IPP) Can Be Reduced by Prostatic Artery Embolization

Background

Prostate artery embolization (PAE) is a new approach to improve lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia. PAE results in global reduction of prostate volume (PV). There are no data available on the efficacy of PAE in reducing intra-vesical prostatic protrusion (IPP), an anatomic feature that is clinically related with bladder outlet obstruction and LUTS.

Objective

To assess the results of PAE in patients with significant IPP due to median lobe hyperplasia and to compare the IPSS decrease and IPP change.

Material and Methods

Prospective analysis of 18 consecutive patients with significant IPP (>5 mm) related to median lobe hyperplasia undergoing PAE using 30–500-μm-calibrated trisacryl microspheres. We measured IPP on sagittal T2-weighted images before and 3 months after PAE. IPSS and clinical results were also evaluated at 3 months.

Results

PAE resulted in significant IPP reduction (1.57 cm ± 0.55 before PAE and 1.30 cm ± 0.46 after PAE, p = 0.0005) (Fig. 1) with no complication. IPSS, quality of life (QoL), total prostate-specific antigen (PSA) level, and PV showed significant reduction after PAE, and maximum urinary flow rate (Q _max) showed significant increase after PAE. No significant change of International Index of Erectile Function (IIEF) for clinical evaluation after PAE. A significant correlation was found between the IPP change and the IPSS change (r = 0.636, p = 0.0045).

Conclusion

Patients had significant IPP reduction as well as significant symptomatic improvement after PAE, and these improvements were positively correlated.

     

前列腺癌的MRI诊断

目的探讨前列腺癌的MRI诊断价值方法回顾性分析30例经手术与病理证实的前列腺癌MRI表现及分期,并与临床病理对照结果前列腺癌80%发生于外周带,T2WI在高信号的前列腺周边带内出现异常结节状低信号,或者前列腺带状结构破坏,周边带与中央带界线消失86.7%的前列腺癌发现已位于C、D期结论磁共振对诊断前列腺癌及其分期具有重要意义